DDInter1042 DDInter1917
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Vandetanib {u} (Compound) resembles {v} (Compound) Erlotinib
Vandetanib {u} (Compound) treats {v} (Disease) thyroid cancer
Vandetanib {u} (Compound) binds {v} (Gene) FMO1
Vandetanib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Vandetanib {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Vandetanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Vandetanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Vandetanib {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Vandetanib (Compound) resembles Erlotinib (Compound)
Vandetanib (Compound) treats thyroid cancer (Disease)
Vandetanib (Compound) binds FMO1 (Gene)
Vandetanib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Vandetanib (Compound) causes Blood creatinine increased (Side Effect)
Vandetanib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Vandetanib may cause a minor interaction that can limit clinical effects when taken with Esomeprazole
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Vandetanib may lead to a major life threatening interaction when taken with Lefamulin